Cancer

The latest news, views and analysis from the pharmaceutical industry’s frontline in the war on cancer. Updates on pharmaceutical and biotech oncology pipelines, regulatory decisions and market access news, and how healthcare systems needs to change to tackle one of the world’s biggest killers.

Cancer/ News/ News/ Oncology

Roche’s Tecentriq loses bladder cancer use as FDA crackdown continues

Richard Staines bladder cancer, cancer, Roche, Tecentriq 0 Comment

Roche’s Tecentriq is the latest medicine to fall foul of a crackdown by the FDA on drugs that

Roche’s Tecentriq loses bladder cancer use as FDA crackdown continues

https://pharmaphorum.com/news/roches-tecentriq-loses-bladder-cancer-use-as-fda-crackdown-continues/

Cancer/ News/ News/ News/ Oncology/ Patients

Scotland backs Pfizer’s Ibrance for breast cancer

Phil Taylor breast cancer, Ibrance, Pfizer, SMC 0 Comment

Pfizer’s Ibrance has been approved for use by the NHS in Scotland as a second-line treatment for advanced

Scotland backs Pfizer’s Ibrance for breast cancer

https://pharmaphorum.com/news/scotland-backs-pfizers-ibrance-for-breast-cancer/

Cancer/ News/ News/ Oncology

Array, Pierre Fabre bowel cancer therapy ‘could replace chemo’

Phil Taylor Array Biopharma, colorectal cancer, Oncology, Pfizer, Pierre Fabre 0 Comment

A new trial has shown for the first time that a combination of three targeted therapies can improve

Array, Pierre Fabre bowel cancer therapy ‘could replace chemo’

https://pharmaphorum.com/news/array-pierre-fabre-bowel-cancer-therapy-could-replace-chemo/

Cancer/ News/ News/ News/ Oncology/ R&D

Puma Biotechnology’s breast cancer drug approved in Europe

Piotr Wnuk breast cancer, HER2-positive breast cancer, Puma Biotechnology 0 Comment

Puma Biotechnology received European Commission (EC) marketing authorisation for Nerlynx (neratinib) in breast cancer, despite earlier European Medicines

Puma Biotechnology’s breast cancer drug approved in Europe

https://pharmaphorum.com/news/ec-approves-puma-breast-cancer-drug/